All mouse models will be made available from JAX. For strains currently available, please see our Strain List.


All datasets developed by MODEL-AD will be available from the AD Knowledge Portal.

This includes gene expression analysis at 4 and 12 months of age, which is used to prioritize those models going to deep phenotyping.

Deep phenotyping will be done at 4, 12, 18, and 24 months of age.  This includes: transcriptomics, proteomics, and metabolomics; neuropathology; in vivo imaging; biomarker analysis;  and behavior/cognitive assays.

Data will be uploaded on an ongoing basis as experiments are completed.  To get notified of new data releases sign up for the AD Knowledge Portal Newsletter.


One of the major challenges in the field of Alzheimer’s Disease is the translation of research performed in model organisms to productive clinical trials. The IU/JAX MODEL-AD group working in collaboration with AMP-AD and NanoString created and validated a 770 gene expression assay for the evaluation of mouse models of AD. The nCounter Mouse AD Panel provides an efficient, reproducible and cost-effective way to monitor disease progression with age, assay potential therapeutics, and screen compounds prior to more detailed pharmacodynamics analysis. IU/JAX MODEL-AD mouse models will be validated using the Mouse AD Panel, with all data made available on the AMP-AD Knowledge Portal. In addition to the Mouse AD Panel, the new Human AD panel is also now available to provide direct comparison of results derived in mouse models to human tissue and characterize AD with a comprehensive, standardized set of 770-genes. Researchers may also customize the panels with 30 additional RNA targets. For more information about NanoString, visit


All protocols used for phenotyping and preclinical testing will be made available as they are validated.


Improving Preclinical Translation of Alzheimer’s Disease Research

This workshop will leverage the expertise and facilities of the Indiana University (IU)/JAX Model Organism Development for Evaluation of Late Onset Alzheimer’s Disease (MODEL-AD) Precision Medicine consortium.  We aim to address training gaps in preclinical drug screening by providing you with the skills and knowledge required for rigorous design, execution, analysis, and reporting of pharmacokinetic, pharmacodynamics, and preclinical efficacy experiments, particularly in the mouse. Through this workshop, you will experience a significant amount of hands-on, practical laboratory training in in vivo drug screening.